UK will offer under-30s alternative to AZ’s COVID jabThe UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca Share XUK will offer under-30s alternative to AZ’s COVID jabhttps://pharmaphorum.com/news/uk-will-offer-under-30s-alternative-to-azs-covid-jab/
Paediatric trial of AZ COVID jab ‘halted as a precaution’Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a Share XPaediatric trial of AZ COVID jab ‘halted as a precaution’https://pharmaphorum.com/news/paediatric-trial-of-az-covid-jab-halted-as-a-precaution/
MHRA launches patient involvement pilot for drug applicationsThe UK drugs regulator is now asking that all applications for new medicines or indications detail the efforts Share XMHRA launches patient involvement pilot for drug applicationshttps://pharmaphorum.com/news/mhra-launches-patient-centric-pilot-for-drug-applications/
Novavax confirms efficacy of COVID-19 jab against UK variantA clinical trial has found that Novavax’ COVID-19 vaccine is 86% protective against the UK variant of SARS-CoV-2, Share XNovavax confirms efficacy of COVID-19 jab against UK varianthttps://pharmaphorum.com/news/novavax-confirms-efficacy-of-covid-19-jab-against-uk-variant/
New era of genomic medicine begins as UK approves Lilly’s RetsevmoThe UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung Share XNew era of genomic medicine begins as UK approves Lilly’s Retsevmohttps://pharmaphorum.com/news/uk-authorises-lillys-ret-targeted-retsevmo/
MHRA approves Seagen’s oral HER2 drug TukysaThe UK drugs regulator has approved Seagen’s Tukysa as a third-line treatment for HER2-positive breast cancer, shortly after Share XMHRA approves Seagen’s oral HER2 drug Tukysahttps://pharmaphorum.com/news/mhra-approves-seagens-oral-her2-drug-tukysa/
2021 – UK market access prospectsWith a new year comes the opportunity to think ahead for the market access landscape for the coming Share X2021 – UK market access prospectshttps://pharmaphorum.com/views-analysis-market-access/2021-uk-market-access-prospects/
Moderna’s COVID-19 vaccine is third approved in UKThe UK has approved the Moderna coronavirus vaccine, hard on the heels of its go-ahead in Europe, although Share XModerna’s COVID-19 vaccine is third approved in UKhttps://pharmaphorum.com/news/modernas-covid-19-vaccine-is-third-approved-in-uk/
AZ COVID-19 vaccine cleared in UK, dosing to start next weekThe UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the Share XAZ COVID-19 vaccine cleared in UK, dosing to start next weekhttps://pharmaphorum.com/news/az-covid-19-vaccine-cleared-in-uk-dosing-to-start-next-week/
